Endothelial cells lining the lumen of blood vessels play an important role in the regulation of cardiovascular functions through releasing both vasoconstricting and vasodilating factors. The production and function of vasoconstricting factors are largely elevated in hypertension, diabetes, atherosclerosis, and ischemia/reperfusion injuries. Cyclooxygenases (COXs) are the major enzymes producing five different prostanoids that act as either contracting or relaxing substances. Under conditions of increased oxidative stress, the expressions and activities of COX isoforms are altered, resulting in changes in production of various prostanoids and thus affecting vascular tone. This review briefly summarizes the relationship between oxidative stress, COXs, and prostanoids, thereby providing new insights into the pathophysiological mechanisms of cardiovascular diseases (CVDs).
Recent Advances:
Many new drugs targeting oxidative stress, COX-2, and prostanoids against common CVDs have been evaluated in recent years and they are summarized in this review.
Critical Issues:
Comprehensive understanding of the complex interplay between oxidative stress, COXs, and prostanoids in CVDs helps develop more effective measures against cardiovascular pathogenesis.
Future Directions:
Apart from minimizing the undesired effects of harmful prostanoids, future studies shall investigate the restoration of vasoprotective prostanoids as a means to combat CVDs. Antioxid. Redox Signal. 34, 784–799.
Get full access to this article
View all access options for this article.
References
1.
Al-ArifiMN, MaayahZH, AlshamraniAA, and KorashyHM. Impact of cigarette smoke exposure on the expression of cardiac hypertrophic genes, cytochrome P450 enzymes, and oxidative stress markers in rats. J Toxicol Sci, 37: 1083–1090, 2012.
2.
AntmanEM, BennettJS, DaughertyA, FurbergC, RobertsH, and TaubertKA. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation, 115: 1634–1642, 2007.
3.
ArehartE, StithamJ, AsselbergsFW, DouvilleK, MacKenzieT, FetalveroKM, GleimS, KaszaZ, RaoY, MartelL, SegelS, RobbJ, KaplanA, SimonsM, PowellRJ, MooreJH, RimmEB, MartinKA, and HwaJ. Acceleration of cardiovascular disease by a dysfunctional prostacyclin receptor mutation: potential implications for cyclooxygenase-2 inhibition. Circ Res, 102: 986–993, 2008.
4.
BatenburgWW, PoppR, FlemingI, de VriesR, GarreldsIM, SaxenaPR, and DanserAHJ. Bradykinin-induced relaxation of coronary microarteries: S-nitrosothiols as EDHF?. Br J Pharmacol, 142: 125–135, 2004.
Candelario-JalilE, AlvarezD, MerinoN, and LeónOS. Delayed treatment with nimesulide reduces measures of oxidative stress following global ischemic brain injury in gerbils. Neurosci Res, 47: 245–253, 2003.
7.
CaugheyGE, ClelandLG, PenglisPS, GambleJR, and JamesMJ. Roles of cyclooxygenase (COX)-1 and COX-2 in prostanoid production by human endothelial cells: selective up-regulation of prostacyclin synthesis by COX-2. J Immunol, 167: 2831–2838, 2001.
8.
ChanCC, ReidCM, AwTJ, LiewD, HaasSJ, and KrumH. Do COX-2 inhibitors raise blood pressure more than nonselective NSAIDs and placebo? An updated meta-analysis. J Hypertens, 27: 2332–2341, 2009.
9.
ChaoCL, ChangNC, WengCS, LeeKR, KaoST, HsuJC, and HoFM. Grape seed extract ameliorates tumor necrosis factor-α-induced inflammatory status of human umbilical vein endothelial cells. Eur J Nutr, 50: 401–409, 2011.
10.
ChenH, MontagnaniM, FunahashiT, ShimomuraI, and QuonMJ. Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem, 278: 45021–45026, 2003.
11.
ChenJ, Champa-RodriguezML, and WoodwardDF. Identification of a prostanoid FP receptor population producing endothelium-dependent vasorelaxation in the rabbit jugular vein. Br J Pharmacol, 116: 3035–3041, 1995.
12.
ChengK, WuTJ, WuKK, SturinoC, MettersK, GottesdienerK, WrightSD, WangZ, O'NeillG, LaiE, and WatersMG. Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. Proc Natl Acad Sci U S A, 103: 6682–6687, 2006.
13.
ChengY, WangM, YuY, LawsonJ, FunkCD, and FitzgeraldGA. Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function. J Clin Invest, 116: 1391–1399, 2006.
14.
CherdonC, RolinS, HansonJ, OomsA, deLevalL, DrionP, MichielsC, PirotteB, MasereelB, SakalihassanN, DefraigneJO, and DognéJM. BM-573 inhibits the development of early atherosclerotic lesions in Apo E deficient mice by blocking TP receptors and thromboxane synthase. Prostaglandins Other Lipid Mediat, 94: 124–132, 2011.
15.
Colín-GonzálezAL, Ortiz-PlataA, Villeda-HernándezJ, BarreraD, Molina-JijónE, Pedraza-ChaverríJ, and MaldonadoPD. Aged garlic extract attenuates cerebral damage and cyclooxygenase-2 induction after ischemia and reperfusion in rats. Plant Foods Hum Nutr, 66: 348–354, 2011.
16.
DasS, KohrM, Dunkerly-EyringB, LeeDI, BedjaD, KentOA, LeungAKL, Henao-MejiaJ, FlavellRA, and SteenbergenC. Divergent effects of miR-181 family members on myocardial function through protective cytosolic and detrimental mitochondrial microRNA targets. J Am Heart Assoc, 6: e004694, 2017.
17.
de Sá FG, de Queiroz DB, Ramos-Alves FE, Santos-Rocha J, daSilva OA, Moreira HS, Leal GA, daRocha MA, Duarte GP, and Xavier FE. Hyperglycaemia in pregnant rats causes sex-related vascular dysfunction in adult offspring: role of cyclooxygenase-2. Exp Physiol, 102: 1019–1036, 2017.
18.
DeebRS, UpmacisRK, LamonBD, GrossSS, and HajjarDP. Maintaining equilibrium by selective targeting of cyclooxygenase pathways: promising offensives against vascular injury. Hypertension, 51: 1–7, 2008.
19.
DhanyaBL, SwathyRP, and IndiraM. Selenium downregulates oxidative stress-induced activation of leukotriene pathway in experimental rats with diabetic cardiac hypertrophy. Biol Trace Elem Res, 161: 107–115, 2014.
20.
DingW, LiuL, WangZ, TangM, TiY, HanL, ZhangL, ZhangY, ZhongM, and ZhangW. FP-receptor gene silencing ameliorates myocardial fibrosis and protects from diabetic cardiomyopathy. J Mol Med (Berl), 92: 629–640, 2014.
21.
DollerA, GauerS, SobkowiakE, GeigerH, PfeilschifterJ, and EberhardtW. Angiotensin II induces renal plasminogen activator inhibitor-1 and cyclooxygenase-2 expression post-transcriptionally via activation of the mRNA-stabilizing factor human-antigen R. Am J Pathol, 174: 1252–1263, 2009.
22.
DongJ, WongSL, LauCW, LeeHK, NgCF, ZhangL, YaoX, ChenZ, VanhouttePM, and HuangY. Calcitriol protects renovascular function in hypertension by down-regulating angiotensin II type 1 receptors and reducing oxidative stress. Eur Heart J, 33: 2980–2990, 2012.
23.
DongJ, WongSL, LauCW, LiuJ, WangYX, HeZD, NgCF, Yu ChenZ, YaoX, XuA, NiX, WangH, and HuangY. Calcitriol restores renovascular function in estrogen-deficient rats through downregulation of cyclooxygenase-2 and the thromboxane-prostanoid receptor. Kidney Int, 84: 54–63, 2013.
24.
DongJ, YuanX, and XieW. Pentoxifylline exerts anti-inflammatory effects on cerebral ischemia reperfusion-induced injury in a rat model via the p38 mitogen-activated protein kinase signaling pathway. Mol Med Rep, 17: 1141–1147, 2018.
25.
DoréS and Shafique AhmadA. Brain Neurotrauma: Molecular, Neuropsychological, and Rehabilitation Aspects. State of Florida: CRC Press, 2015, Ch.10.
26.
DouL, SalléeM, CeriniC, PoitevinS, GondouinB, Jourde-ChicheN, FallagueK, BrunetP, CalafR, DussolB, MalletB, Dignat-GeorgeF, and BurteyS. The cardiovascular effect of the uremic solute indole-3 acetic acid. J Am Soc Nephrol, 26: 876–887, 2015.
27.
DrescherC, DiestelA, WollersheimS, BergerF, and SchmittKRL. How does hypothermia protect cardiomyocytes during cardioplegic ischemia?. Eur J Cardiothorac Surg, 40: 352–359, 2011.
28.
DrouinA, FarhatN, BolducV, Thorin-TrescasesN, GillisMA, VilleneuveL, NguyenA, and ThorinE. Up-regulation of thromboxane A2 impairs cerebrovascular eNOS function in aging atherosclerotic mice. Pflugers Arch, 462: 371–383, 2011.
29.
EdmundsE and LipGYH. Cardiovascular risk in women: the cardiologist's perspective. QJM, 93: 135–145, 2000.
30.
ElmarakbyAA and ImigJD. Obesity is the major contributor to vascular dysfunction and inflammation in high-fat diet hypertensive rats. Clin Sci, 118: 291–301, 2010.
31.
FélétouM, CohenRA, VanhouttePM, and VerbeurenTJ. TP receptors and oxidative stress. In: Advances in Pharmacology, edited by Vanhoutte PM. San Diego: Elsevier, Inc., 2010, pp. 85–106.
FélétouM, HuangY, and VanhouttePM. Endothelium-mediated control of vascular tone: COX-1 and COX-2 products. Br J Pharmacol, 164: 894, 2011.
34.
FengJ, AndersonK, SinghAK, EhsanA, MitchellH, LiuY, and SellkeFW. Diabetes upregulation of cyclooxygenase 2 contributes to altered coronary reactivity after cardiac surgery. Ann Thorac Surg, 104: 568–576, 2017.
35.
GluaisP, LonchamptM, MorrowJD, VanhouttePM, and FeletouM. Acetylcholine-induced endothelium-dependent contractions in the SHR aorta: the Janus face of prostacyclin. Br J Pharmacol, 146: 834–845, 2005.
36.
Gómez-GuzmánM, JiménezR, SánchezM, RomeroM, O'ValleF, Lopez-SepulvedaR, QuintelaAM, GalindoP, ZarzueloMJ, BailónE, DelpónE, Perez-VizcainoF, and DuarteJ. Chronic (-)-epicatechin improves vascular oxidative and inflammatory status but not hypertension in chronic nitric oxide-deficient rats. Br J Nutr, 106: 1337–1348, 2011.
37.
Günal Ö, AktanAÖ, YegenC, KurtelH, and YalinR. Captopril prevents the oxidative damage to proteins after renal ischemia reperfusion injury: role of endothelin-1. Prostaglandins Leukot Essent Fatty Acids, 56: 23–27, 1997.
38.
HalladinNL. Oxidative and inflammatory biomarkers of ischemia and reperfusion injuries. Dan Med J, 62: B5054, 2015.
39.
HaraS, KameiD, SasakiY, TanemotoA, and NakataniY. Prostaglandin E synthases: understanding their pathophysiological roles through mouse genetic models. Biochimie, 92: 651–659, 2010.
40.
HardingP and LaPointeMC. Prostaglandin E2 increases cardiac fibroblast proliferation and increases cyclin D expression via EP1 receptor. Prostaglandins Leukot Essent Fatty Acids, 84: 147–152, 2011.
41.
HermannM, CamiciG, FrattonA, HurlimannD, TannerFC, HellermannJP, FiedlerM, ThieryJ, NeidhartM, GayRE, GayS, LüscherTF, and RuschitzkaF. Differential effects of selective cyclooxygenase-2 inhibitors on endothelial function in salt-induced hypertension. Circulation, 108: 2308–2311, 2003.
42.
HernanzR, BrionesAM, AlonsoMJ, VilaE, and SalaicesM. Hypertension alters role of iNOS, COX-2, and oxidative stress in bradykinin relaxation impairment after LPS in rat cerebral arteries. Am J Physiol Circ Physiol, 287: H225–H234, 2004.
43.
HernanzR, BrionesAM, SalaicesM, and AlonsoMJ. New roles for old pathways? A circuitous relationship between reactive oxygen species and cyclo-oxygenase in hypertension. Clin Sci, 126: 111–121, 2014.
44.
HernanzR, Martín Á, Pérez-GirónJV, PalaciosR, BrionesAM, MiguelM, SalaicesM, and AlonsoMJ. Pioglitazone treatment increases COX-2-derived prostacyclin production and reduces oxidative stress in hypertensive rats: role in vascular function. Br J Pharmacol, 166: 1303–1319, 2012.
45.
HseuYC, Senthil KumarKJ, ChenCS, ChoHJ, LinSW, ShenPC, LinCW, LuFJ, and YangHL. Humic acid in drinking well water induces inflammation through reactive oxygen species generation and activation of nuclear factor-κB/activator protein-1 signaling pathways: a possible role in atherosclerosis. Toxicol Appl Pharmacol, 274: 249–262, 2014.
46.
HudsonM, RichardH, and PiloteL. Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study. BMJ, 330: 1370, 2005.
47.
HusainK, SuarezE, IsidroA, and FerderL. Effects of paricalcitol and enalapril on atherosclerotic injury in mouse aortas. Am J Nephrol, 32: 296–304, 2010.
48.
This reference has been deleted.
49.
This reference has been deleted.
50.
KanayamaM, YamaguchiS, ShibataT, ShibataN, KobayashiM, NagaiR, AraiH, TakahashiK, and UchidaK. Identification of a serum component that regulates cyclooxygenase-2 gene expression in cooperation with 4-hydroxy-2-nonenal. J Biol Chem, 282: 24166–24174, 2007.
51.
KanellakisP, PomilioG, WalkerC, HusbandA, HuangJL, NestelP, AgrotisA, and BobikA. A novel antioxidant 3,7-dihydroxy-isoflav-3-ene (DHIF) inhibits neointimal hyperplasia after vessel injury attenuating reactive oxygen species and nuclear factor-κB signaling. Atherosclerosis, 204: 66–72, 2009.
52.
KaoMC, JanWC, TsaiPS, WangTY, and HuangCJ. Magnesium sulfate mitigates lung injury induced by bilateral lower limb ischemia-reperfusion in rats. J Surg Res, 171: e97–e106, 2011.
53.
KatselouMG, MatralisAN, and KourounakisAP. Developing potential agents against atherosclerosis: design, synthesis and pharmacological evaluation of novel dual inhibitors of oxidative stress and squalene synthase activity. Eur J Med Chem, 138: 748–760, 2017.
54.
KelloggAP, ConversoK, WigginT, StevensM, and Pop-BusuiR. Effects of cyclooxygenase-2 gene inactivation on cardiac autonomic and left ventricular function in experimental diabetes. Am J Physiol Circ Physiol, 296: H453–H461, 2009.
55.
KennedyCR, ZhangY, BrandonS, GuanY, CoffeeK, FunkCD, MagnusonMA, OatesJA, BreyerMD, and BreyerRM. Salt-sensitive hypertension and reduced fertility in mice lacking the prostaglandin EP2 receptor. Nat Med, 5: 217–220, 1999.
56.
KinraM, MudgalJ, AroraD, and NampoothiriM. An insight into the role of cyclooxygenase and lipooxygenase pathway in renal ischemia. Eur Rev Med Pharmacol Sci, 21: 5017–5020, 2017.
57.
KishimotoK, LiRC, ZhangJ, KlausJA, KiblerKK, DoréS, KoehlerRC, and SapirsteinA. Cytosolic phospholipase A2 alpha amplifies early cyclooxygenase-2 expression, oxidative stress and MAP kinase phosphorylation after cerebral ischemia in mice. J Neuroinflammation, 7: 42, 2010.
58.
KodaN, TsutsuiY, NiwaH, ItoS, WoodwardDF, and WatanabeK. Synthesis of prostaglandin F ethanolamide by prostaglandin F synthase and identification of Bimatoprost as a potent inhibitor of the enzyme: new enzyme assay method using LC/ESI/MS. Arch Biochem Biophys, 424: 128–136, 2004.
59.
Komoto J, Yamada T, Watanabe‖ K, Woodward DF, and Takusagawa F. Prostaglandin F2α formation from prostaglandin H2 by prostaglandin F synthase (PGFS): crystal structure of PGFS containing bimatoprost. Biochemistry, 45: 1987–1996, 2006.
60.
Kudo I and Murakami M. Prostaglandin E synthase, a terminal enzyme for prostaglandin E2 biosynthesis. J Biochem Mol Biol, 38: 633–638, 2005.
61.
KunakCS, KukulaO, MutluE, GençF, PekerGG, KuyrukluyıldızU, BiniciO, AltunerD, and AlpHH. The effect of etoricoxib on hepatic ischemia-reperfusion injury in rats. Oxid Med Cell Longev, 2015: 598162, 2015.
62.
LeeCH, KimSH, and LeeSM. Effect of pyrrolidine dithiocarbamate on hepatic vascular stress gene expression during ischemia and reperfusion. Eur J Pharmacol, 595: 100–107, 2008.
63.
LiW, WuS, AhmadM, JiangJ, LiuH, NagayamaT, RoseME, TyurinVA, TyurinaYY, BorisenkoGG, BelikovaN, ChenJ, KaganVE, and GrahamSH. The cyclooxygenase site, but not the peroxidase site of cyclooxygenase-2 is required for neurotoxicity in hypoxic and ischemic injury. J Neurochem, 113: 965–977, 2010.
64.
LiangC, ZhangY, ZhuoD, LoCY, YuL, LauCW, KwanYW, TseG, HuangY, and YaoX. Endothelial cell transient receptor potential channel C5 (TRPC5) is essential for endothelium-dependent contraction in mouse carotid arteries. Biochem Pharmacol, 159: 11–24, 2019.
65.
LiuHB, MengQH, HuangC, WangJB, and LiuXW. Nephroprotective effects of polydatin against ischemia/reperfusion injury: a role for the PI3K/Akt signal pathway. Oxid Med Cell Longev, 2015: 362158, 2015.
66.
LiuL, LiuJ, TianXY, WongWT, LauCW, XuA, XuG, NgCF, YaoX, GaoY, and HuangY. Uncoupling protein-2 mediates DPP-4 inhibitor-induced restoration of endothelial function in hypertension through reducing oxidative stress. Antioxid Redox Signal, 21: 1571–1581, 2014.
67.
LiuS, JiY, YaoJ, ZhaoX, XuH, GuanY, BreyerRM, ShengH, and ZhuJ. Knockout of the prostaglandin E2 receptor subtype 3 promotes eccentric cardiac hypertrophy and fibrosis in mice. J Cardiovasc Pharmacol Ther, 22: 71–82, 2017.
68.
LoftinCD, TrivediDB, TianoHF, ClarkJA, LeeCA, EpsteinJA, MorhamSG, BreyerMD, NguyenM, HawkinsBM, GouletJL, SmithiesO, KollerBH, and LangenbachR. Failure of ductus arteriosus closure and remodeling in neonatal mice deficient in cyclooxygenase-1 and cyclooxygenase-2. Proc Natl Acad Sci U S A, 98: 1059–1064, 2001.
69.
MaM, UekawaK, HasegawaY, NakagawaT, KatayamaT, SuetaD, ToyamaK, KataokaK, KoibuchiN, KuratsuJ, and Kim-MitsuyamaS. Pretreatment with rosuvastatin protects against focal cerebral ischemia/reperfusion injury in rats through attenuation of oxidative stress and inflammation. Brain Res, 1519: 87–94, 2013.
70.
MadamanchiNR, VendrovA, and RungeMS. Oxidative stress and vascular disease. Arterioscler Thromb Vasc Biol, 25: 29–38, 2005.
71.
MartinezCS, PiagetteJT, EscobarAG, Martín Á, PalaciosR, PeçanhaFM, VassalloDV, ExleyC, AlonsoMJ, MiguelM, SalaicesM, and WiggersGA. Aluminum exposure at human dietary levels promotes vascular dysfunction and increases blood pressure in rats: a concerted action of NAD(P)H oxidase and COX-2. Toxicology, 390: 10–21, 2017.
72.
Martínez-RevellesS, AvendañoMS, García-RedondoAB, ÁlvarezY, AguadoA, Pérez-GirónJV, García-RedondoL, EstebanV, RedondoJM, AlonsoMJ, BrionesAM, and SalaicesM. Reciprocal relationship between reactive oxygen species and cyclooxygenase-2 and vascular dysfunction in hypertension. Antioxid Redox Signal, 18: 51–65, 2013.
73.
MathewRO, BangaloreS, LavelleMP, PellikkaPA, SidhuMS, BodenWE, and AsifA. Diagnosis and management of atherosclerotic cardiovascular disease in chronic kidney disease: a review. Kidney Int, 91: 797–807, 2017.
74.
McCulloughPA, VasudevanA, LopezLR, SwiftC, PetersonM, Bennett-FirminJ, SchiffmannR, and BottiglieriT. Oxidative stress reflected by increased F2-isoprostanes is associated with increasing urinary 11-dehydro thromboxane B2 levels in patients with coronary artery disease. Thromb Res, 148: 85–88, 2016.
75.
MillerJD, PeottaVA, ChuY, WeissRM, ZimmermanK, BrooksRM, and HeistadDD. MnSOD protects against COX1-mediated endothelial dysfunction in chronic heart failure. Am J Physiol Circ Physiol, 298: H1600–H1607, 2010.
76.
MukaiY and SatoS. Polyphenol-containing azuki bean (Vigna angularis) seed coats attenuate vascular oxidative stress and inflammation in spontaneously hypertensive rats. J Nutr Biochem, 22: 16–21, 2011.
77.
MuñozM, SánchezA, Pilar MartínezM, BeneditoS, López-OlivaME, García-SacristánA, HernándezM, and PrietoD. COX-2 is involved in vascular oxidative stress and endothelial dysfunction of renal interlobar arteries from obese Zucker rats. Free Radic Biol Med, 84: 77–90, 2015.
78.
MurakamiM, NakataniY, TaniokaT, and KudoI. Prostaglandin E synthase. Prostaglandins Other Lipid Mediat, 68–69: 383–399, 2002.
79.
MutoA, NishibeT, MiyauchiY, KondoY, YamamotoY, DardikA, and ShigematsuH. Prostaglandin receptors EP2 and IP are detectable in atherosclerotic arteries and plaques. Int Angiol, 29: 43–48, 2010.
80.
MuzaffarS, ShuklaN, MasseyY, AngeliniGD, and JeremyJY. NADPH oxidase 1 mediates upregulation of thromboxane A2 synthase in human vascular smooth muscle cells: inhibition with iloprost. Eur J Pharmacol, 658: 187–192, 2011.
81.
NakataniY, HokonoharaY, KakutaS, SudoK, IwakuraY, and KudoI. Knockout mice lacking cPGES/p23, a constitutively expressed PGE2 synthetic enzyme, are peri-natally lethal. Biochem Biophys Res Commun, 362: 387–392, 2007.
82.
NieD, LambertiM, ZacharekA, LiL, SzekeresK, TangK, ChenY, and HonnKV. Thromboxane A2 regulation of endothelial cell migration, angiogenesis, and tumor metastasis. Biochem Biophys Res Commun, 267: 245–251, 2000.
83.
NishikataR, KatoN, and HiraiwaK. Oxidative stress may be involved in distant organ failure in tourniquet shock model mice. Leg Med, 16: 70–75, 2014.
OgawaM, SuzukiJI, KosugeH, TakayamaK, NagaiR, and IsobeM. The mechanism of anti-inflammatory effects of prostaglandin E2 receptor 4 activation in murine cardiac transplantation. Transplantation, 87: 1645–1653, 2009.
86.
OksuzE, AtalarF, TanırverdiG, BilirA, ShahzadiA, and YaziciZ. Therapeutic potential of cyclooxygenase-3 inhibitors in the management of glioblastoma. J Neurooncol, 126: 271–278, 2016.
87.
OuedraogoR, WuX, XuSQ, FuchselL, MotoshimaH, MahadevK, HoughK, ScaliaR, and GoldsteinBJ. Adiponectin suppression of high-glucose-induced reactive oxygen species in vascular endothelial cells: evidence for involvement of a cAMP signaling pathway. Diabetes, 55: 1840–1846, 2006.
88.
OyagbemiAA, OmobowaleTO, AwoyomiOV, AjibadeTO, FalayiOO, OgunpoluBS, OkotieUJ, AsenugaER, AdejumobiOA, HassanFO, Ola-DaviesOE, SabaAB, AdedapoAA, and YakubuMA. Cobalt chloride toxicity elicited hypertension and cardiac complication via induction of oxidative stress and upregulation of COX-2/Bax signaling pathway. Hum Exp Toxicol, 38: 519–532, 2019.
89.
OzenG, GomezI, DaciA, DeschildreC, BoubayaL, TeskinO, Uydeş-DoğanBS, JakobssonPJ, LongroisD, TopalG, and NorelX. Inhibition of microsomal PGE synthase-1 reduces human vascular tone by increasing PGI2: a safer alternative to COX-2 inhibition. Br J Pharmacol, 174: 4087–4098, 2017.
90.
PacherP, BeckmanJS, and LiaudetL. Nitric oxide and peroxynitrite in health and disease. Physiol Rev, 87: 315–424, 2007.
91.
ParaviciniTM and TouyzRM. NADPH oxidases, reactive oxygen species, and hypertension: clinical implications and therapeutic possibilities. Diabetes Care, 31: S170–S180, 2008.
92.
ParkJY, PillingerMH, and AbramsonSB. Prostaglandin E2 synthesis and secretion: the role of PGE2 synthases. Clin Immunol, 119: 229–240, 2006.
93.
Pérez-AsensioFJ, dela RosaX, Jiménez-AltayóF, GorinaR, MartínezE, MesseguerA, VilaE, ChamorroA, and PlanasAM. Antioxidant CR-6 protects against reperfusion injury after a transient episode of focal brain ischemia in rats. J Cereb Blood Flow Metab, 30: 638–652, 2010.
94.
Perez-PoloJR, ReillyCB, and ReaHC. Oxygen resuscitation after hypoxia ischemia stimulates prostaglandin pathway in rat cortex. Int J Dev Neurosci, 29: 639–644, 2011.
95.
QianJY, HardingP, LiuY, SheselyE, YangXP, and LaPointeMC. Reduced cardiac remodeling and function in cardiac-specific EP4 receptor knockout mice with myocardial infarction. Hypertension, 51: 560–566, 2008.
96.
RajaL, PalaniveluS, and PanchanathamS. Anti-inflammatory property of Kalpaamruthaa on myocardium in type 2 diabetes mellitus induced cardiovascular complication. Immunopharmacol Immunotoxicol, 35: 119–125, 2013.
97.
RicciottiE, YuY, GrosserT, and FitzgeraldGA. COX-2, the dominant source of prostacyclin. Proc Natl Acad Sci U S A, 110: E183, 2013.
98.
RomeroM, Leon-GomezE, LobyshevaI, RathG, DognéJM, FeronO, and DessyC. Effects of BM-573 on endothelial dependent relaxation and increased blood pressure at early stages of atherosclerosis. PLoS One, 11: e0152579, 2016.
99.
RoumieCL, MitchelEF, KaltenbachL, ArbogastPG, GideonP, and GriffinMR. Nonaspirin NSAIDs, cyclooxygenase 2 inhibitors, and the risk for stroke. Stroke, 39: 2037–2045, 2008.
100.
This reference has been deleted.
101.
SakrHF, AbbasAM, and Bin-JaliahI. Modulation of the neurological and vascular complications by grape seed extract in a rat model of spinal cord ischemia–reperfusion injury by downregulation of both osteopontin and cyclooxygenase-2. Can J Physiol Pharmacol, 94: 719–727, 2016.
102.
SanmuganathanPS, GhahramaniP, JacksonPR, WallisEJ, and RamsayLE. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. Heart, 85: 265–271, 2001.
103.
SedaghatZ, KadkhodaeeM, SeifiB, and AhghariP. Hepatoprotective effects of remote perconditioning during renal ischemia. Bratislava Med J, 115: 675–679, 2014.
SenaCM, PereiraAM, and SeiçaR. Endothelial dysfunction—a major mediator of diabetic vascular disease. Biochim Biophys Acta, 1832: 2216–2231, 2013.
106.
ShenH, OesterlingE, StrombergA, ToborekM, MacDonaldR, and HennigB. Zinc deficiency induces vascular pro-inflammatory parameters associated with NF-kappaB and PPAR signaling. J Am Coll Nutr, 27: 577–587, 2008.
107.
ShinmuraK. Is adiponectin a bystander or a mediator in heart failure? The tangled thread of a good-natured adipokine in aging and cardiovascular disease. Heart Fail Rev, 15: 457–466, 2010.
108.
SilvaLAC, Veira-FilhoLD, BarretoISS, CabralEV, VieyraA, and PaixãoADO. Prenatal undernutrition changes renovascular responses of nimesulide in rat kidneys. Basic Clin Pharmacol Toxicol, 108: 115–121, 2011.
109.
SimmonsGH, PadillaJ, and LaughlinMH. Heterogeneity of endothelial cell phenotype within and amongst conduit vessels of the swine vasculature. Exp Physiol, 97: 1074–1082, 2012.
110.
SmythEM and FitzGeraldGA. Human prostacyclin receptor. Vitam Horm, 65: 149–165, 2002.
111.
SongWL, RicciottiE, LiangX, GrosserT, GrantGR, and FitzGeraldGA. Lipocalin-like prostaglandin D synthase but not hemopoietic prostaglandin D synthase deletion causes hypertension and accelerates thrombogenesis in mice. J Pharmacol Exp Ther, 367: 425–432, 2018.
StoffelsB, YonezawaK, YamamotoY, SchäferN, OverhausM, KlingeU, KalffJC, MinorT, and TolbaRH. Meloxicam, a COX-2 inhibitor, ameliorates ischemia/reperfusion injury in non-heart-beating donor livers. Eur Surg Res, 47: 109–117, 2011.
114.
SuleymanB, AlbayrakA, KurtN, DemirciE, GundogduC, and AksoyM. The effect of etoricoxib on kidney ischemia-reperfusion injury in rats: a biochemical and immunohistochemical assessment. Int Immunopharmacol, 23: 179–185, 2014.
TabassumR, VaibhavK, ShrivastavaP, KhanA, AhmedME, AshafaqM, KhanMB, IslamF, SafhiMM, and IslamF. Perillyl alcohol improves functional and histological outcomes against ischemia-reperfusion injury by attenuation of oxidative stress and repression of COX-2, NOS-2 and NF-κB in middle cerebral artery occlusion rats. Eur J Pharmacol, 747: 190–199, 2015.
117.
TakasuC, VaziriND, LiS, RoblesL, VoK, TakasuM, PhamC, FarzanehSH, ShimadaM, StamosMJ, and IchiiH. Treatment with dimethyl fumarate ameliorates liver ischemia/reperfusion injury. World J Gastroenterol, 23: 4508–4516, 2017.
118.
Teixeira-da-SilvaJJ, Nunes-MoreiraHS, SilvaCO, LahlouS, NaroF, XavierFE, and DuarteGP. Chronic administration of sildenafil improves endothelial function in spontaneously hypertensive rats by decreasing COX-2 expression and oxidative stress. Life Sci, 225: 29–38, 2019.
119.
TesfamariamB, BrownML, DeykinD, and CohenRA. Elevated glucose promotes generation of endothelium-derived vasoconstrictor prostanoids in rabbit aorta. J Clin Invest, 85: 929–932, 1990.
TimmersL, SluijterJPG, VerlaanCWJ, SteendijkP, CramerMJ, EmonsM, StrijderC, GründemanPF, SzeSK, HuaL, PiekJJ, BorstC, PasterkampG, and de KleijnDPV. Cyclooxygenase-2 inhibition increases mortality, enhances left ventricular remodeling, and impairs systolic function after myocardial infarction in the pig. Circulation, 115: 326–332, 2007.
122.
TouchberryCD, SilswalN, TchikrizovV, ElmoreCJ, SrinivasS, AktharAS, SwanHK, WetmoreLA, and WackerMJ. Cardiac thromboxane A2 receptor activation does not directly induce cardiomyocyte hypertrophy but does cause cell death that is prevented with gentamicin and 2-APB. BMC Pharmacol Toxicol, 15: 73, 2014.
123.
TsuboiK, SugimotoY, and IchikawaA. Prostanoid receptor subtypes. Prostaglandins Other Lipid Mediat, 68–69: 535–556, 2002.
124.
UchidaK. A lipid-derived endogenous inducer of COX-2: a bridge between inflammation and oxidative stress. Mol Cells, 25: 347–351, 2008.
VanhouttePM. Endothelium-dependent contractions in hypertension: when prostacyclin becomes ugly. Hypertension, 57: 526–531, 2011.
127.
VaziriND, BaiY, YuanJ, SaidHL, SigalaW, and NiZ. ApoA-1 mimetic peptide reverses uremia-induced upregulation of pro-atherogenic pathways in the aorta. Am J Nephrol, 32: 201–211, 2010.
128.
VillegasI, MartínAR, TomaW, and dela LastraCA. Rosiglitazone, an agonist of peroxisome proliferator-activated receptor gamma, protects against gastric ischemia-reperfusion damage in rats: role of oxygen free radicals generation. Eur J Pharmacol, 505: 195–203, 2004.
129.
VirdisA, BaccaA, ColucciR, DurantiE, FornaiM, MaterazziG, IppolitoC, BernardiniN, BlandizziC, BerniniG, and TaddeiS. Endothelial dysfunction in small arteries of essential hypertensive patients: role of cyclooxygenase-2 in oxidative stress generation. Hypertension, 62: 337–344, 2013.
130.
WangF, LuX, PengK, DuY, ZhouSF, ZhangA, and YangT. Prostaglandin E-prostanoid4 receptor mediates angiotensin II–induced (pro)renin receptor expression in the rat renal medulla. Hypertension, 64: 369–377, 2014.
131.
WangM, LeeE, SongW, RicciottiE, RaderDJ, LawsonJA, PuréE, and FitzGeraldGA. Microsomal prostaglandin E synthase-1 deletion suppresses oxidative stress and angiotensin II-induced abdominal aortic aneurysm formation. Circulation, 117: 1302–1309, 2008.
132.
WenceslauCF and RossoniLV. Rostafuroxin ameliorates endothelial dysfunction and oxidative stress in resistance arteries from deoxycorticosterone acetate-salt hypertensive rats. J Hypertens, 32: 542–554, 2014.
133.
WilloughbyDA, MooreAR, and Colville-NashPR. COX-1, COX-2, and COX-3 and the future treatment of chronic inflammatory disease. Lancet, 355: 646–648, 2000.
134.
WongMSK and VanhouttePM. COX-mediated endothelium-dependent contractions: from the past to recent discoveries. Acta Pharmacol Sin, 31: 1095–1102, 2010.
135.
WongSL, LeungFP, LauCW, AuCL, YungLM, YaoX, ChenZY, VanhouttePM, GollaschM, and HuangY. Cyclooxygenase-2–derived prostaglandin F2α mediates endothelium-dependent contractions in the aortae of hamsters with increased impact during aging. Circ Res, 104: 228–235, 2009.
136.
WongSL, WongWT, TianXY, LauCW, and HuangY. Prostaglandins in action indispensable roles of cyclooxygenase-1 and -2 in endothelium-dependent contractions. Adv Pharmacol, 60: 61–83, 2010.
137.
WongWT, TianXY, ChenY, LeungFP, LiuL, LeeHK, NgCF, XuA, YaoX, VanhouttePM, TipoeGL, and HuangY. Bone morphogenic protein-4 impairs endothelial function through oxidative stress–dependent cyclooxygenase-2 upregulation. Circ Res, 107: 984–991, 2010.
138.
WongWT, TianXY, and HuangY. Endothelial dysfunction in diabetes and hypertension. J Cardiovasc Pharmacol, 61: 204–214, 2013.
139.
WuKK and LiouJY. Cellular and molecular biology of prostacyclin synthase. Biochem Biophys Res Commun, 338: 45–52, 2005.
140.
WuR, DucheminS, LaplanteMA, DeChamplainJ, and GirouardH. Cyclo-oxygenase-2 knockout genotype in mice is associated with blunted angiotensin II-induced oxidative stress and hypertension. Am J Hypertens, 24: 1239–1244, 2011.
141.
WuR, LaplanteMA, and deChamplainJ. Cyclooxygenase-2 inhibitors attenuate angiotensin II-induced oxidative stress, hypertension, and cardiac hypertrophy in rats. Hypertension, 45: 1139–1144, 2005.
142.
XiaoCY, YuhkiK, HaraA, FujinoT, KuriyamaS, YamadaT, TakayamaK, TakahataO, KaribeH, TaniguchiT, NarumiyaS, and UshikubiF. Prostaglandin E2 protects the heart from ischemia-reperfusion injury via Its receptor subtype EP4. Circulation, 109: 2462–2468, 2004.
143.
XiaoL, DongJH, JinS, XueHM, GuoQ, TengX, and WuYM. Hydrogen sulfide improves endothelial dysfunction via downregulating BMP4/COX-2 pathway in rats with hypertension. Oxid Med Cell Longev, 2016: 1–10, 2016.
144.
YangCC, ChenKH, HsuP, and ChienCT. Augmented renal prostacyclin by intrarenal bicistronic cyclo-oxygenase-1/prostacyclin synthase gene transfer attenuates renal ischemia-reperfusion injury. Transplant J, 96: 1043–1051, 2013.
145.
YangG and ChenL. An update of microsomal prostaglandin E synthase-1 and PGE2 receptors in cardiovascular health and diseases. Oxid Med Cell Longev, 2016: 1–9, 2016.
146.
YangJ, AhnHN, ChangM, NarasimhanP, ChanPH, and SongYS. Complement component 3 inhibition by an antioxidant is neuroprotective after cerebral ischemia and reperfusion in mice. J Neurochem, 124: 523–535, 2013.
147.
YoonSJ, YoonYW, LeeBK, KwonHM, HwangKC, KimM, ChangW, HongBK, LeeYH, ParkSJ, MinPK, and RimSJ. Potential role of HMG CoA reductase inhibitor on oxidative stress induced by advanced glycation endproducts in vascular smooth muscle cells of diabetic vasculopathy. Exp Mol Med, 41: 802, 2009.
148.
YunN, KangJW, and LeeSM. Protective effects of chlorogenic acid against ischemia/reperfusion injury in rat liver: molecular evidence of its antioxidant and anti-inflammatory properties. J Nutr Biochem, 23: 1249–1255, 2012.
149.
ZhangY and YangY. Arctigenin exerts protective effects against myocardial infarction via regulation of iNOS, COX-2, ERK1/2 and HO-1 in rats. Mol Med Rep, 17: 4839–4845, 2018.
